Blinatumomab
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
B-Cell Acute Lymphoblastic Leukaemia
Conditions
B-Cell Acute Lymphoblastic Leukaemia, ALL, Adult, B-ALL
Trial Timeline
Feb 14, 2020 → Nov 12, 2024
NCT ID
NCT03751709About Blinatumomab
Blinatumomab is a phase 1 stage product being developed by Amgen for B-Cell Acute Lymphoblastic Leukaemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03751709. Target conditions include B-Cell Acute Lymphoblastic Leukaemia, ALL, Adult, B-ALL.
What happened to similar drugs?
3 of 20 similar drugs in B-Cell Acute Lymphoblastic Leukaemia were approved
Approved (3) Terminated (2) Active (15)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02187354 | Pre-clinical | Completed |
| NCT07192237 | Phase 2 | Recruiting |
| NCT07134088 | Phase 1/2 | Recruiting |
| NCT06649006 | Phase 1 | Completed |
| NCT06054113 | Phase 2 | Active |
| NCT04448834 | Phase 2 | Withdrawn |
| NCT04506086 | Approved | Terminated |
| NCT04746209 | Phase 2 | Recruiting |
| NCT04521231 | Phase 1/2 | Recruiting |
| NCT04556084 | Phase 2 | Terminated |
| NCT04785547 | Phase 2 | Terminated |
| NCT04044560 | Phase 2 | Terminated |
| NCT03751709 | Phase 1 | Completed |
| NCT03298412 | Phase 2 | Terminated |
| NCT02961881 | Phase 1 | Completed |
| NCT02910063 | Phase 2/3 | Completed |
| NCT02807883 | Phase 2 | Completed |
| NCT02811679 | Phase 2 | Terminated |
| NCT02412306 | Phase 1/2 | Completed |
| NCT02000427 | Phase 2 | Completed |
Competing Products
20 competing products in B-Cell Acute Lymphoblastic Leukaemia